Please select the option that best describes you:

Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?  



Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Memorial Sloan Kettering Cancer Center
Excellent points Dr. @Patel. Would add one counter...
Radiation Oncologist at Lafayette Radiation Center
Great summary, good links. Like Dr. @Janopaul-Nayl...
Radiation Oncologist at National Institutes of Health Clinical Center
Great points - I agree patient preferences are com...
Radiation Oncologist at Lafayette Radiation Center
The payment issue was a big deal for us a couple o...
Sign in or Register to read more